Update on Hib Vaccine Recall
Hib Vaccine Supply and Interim Recommendations for Use of Hib Vaccines

The recent suspension of production by Merck & Co., Inc. of PedvaxHIB® and Comvax® and Merck's subsequent voluntary recall of certain lots of both vaccines on December 13th have led to a significant disruption in the supply of Haemophilus influenzae type b (Hib) containing vaccines.

The Centers for Disease Control and Prevention (CDC) is making some Hib vaccine available from its stockpile and sanofi pasteur is increasing production of its licensed Hib vaccines, ActHIB® and TriHIBit® (DTaP/Hib) to attempt to meet the current demand for Hib vaccine in the United States.

However, a significant temporary shortage of Hib containing vaccines is now expected. AAP has been working with the CDC and other stakeholders to develop an interim strategy to best meet the needs of children during the shortage. A CDC Dispatch published today in Morbidity and Mortality Weekly Report provides additional details on the expected shortage and interim recommendations.